M42

What M42 does

M42 is a global tech-enabled health company headquartered in Abu Dhabi, formed in 2023 through the merger of G42 Healthcare and Mubadala Health under the Mubadala Investment Company sovereign umbrella. The company operates four integrated platforms—Global Patient Care, Digital Health Solutions, Integrated Health Solutions, and AI Life Sciences—spanning 480 facilities across 27 countries, serving approximately 15 million patients annually with a workforce of roughly 20,000 employees. Its care delivery portfolio includes Cleveland Clinic Abu Dhabi (a 394-bed tertiary hospital ranked #1 in the UAE/GCC by Newsweek), Diaverum (world's third-largest dialysis provider with 450 facilities acquired for $2.5 billion in 2023), Danat Al Emarat, Moorfields Eye Hospital Abu Dhabi, Imperial College London Diabetes Centre, Healthpoint, National Reference Laboratory, Amana Healthcare, and HealthPlus.

M42's core technology stack combines proprietary AI with population-scale health data. Flagship assets include the Med42 70B-parameter open-access Clinical LLM (developed with Cerebras, Core42, and MBZUAI; 72% on USMLE Sample Exam), the Malaffi Health Information Exchange integrating 90+ EMR systems across 3,000+ Abu Dhabi facilities with 3 billion+ clinical records, the OSSI ambient AI clinical assistant built on Microsoft Azure, the Emirati Genome Programme (850,000+ sequenced genomes covering nearly three-quarters of the Emirati population), the Abu Dhabi Biobank, Biogenix Labs for precision genomics, and the IROS Contract Research Organization. AI is deployed across NLP, computer vision (Qritive prostate cancer diagnostics, AIRIS-TB radiology), generative AI, predictive analytics, and process automation, with an open-access research strategy (Med42 on Hugging Face, kidney.com free to consumers).

M42's business model is hybrid: (1) healthcare services revenue from 15 million annual patients via tertiary care, dialysis, primary care, specialty centers, and diagnostics—funded through insurance reimbursements, out-of-pocket payments, and government healthcare contracts; (2) B2B enterprise technology sales of genomic sequencing, AI patient management platforms, and pharmacogenomics to governments (Uzbekistan preliminary agreements, Jordan, Saudi Arabia, U.S. plans) and pharmaceutical companies; (3) medical tourism at Cleveland Clinic Abu Dhabi (35% international patient growth in 2024, over 10,000 encounters from Kuwait, Saudi Arabia, Pakistan, Bahrain, and USA); and (4) partnership-driven research and biopharma services (AstraZeneca, Arcera, Juvenescence, Mammoth Biosciences). Pricing is quote-based for services with no public tiers, while Med42 is open-access for non-commercial research and kidney.com is free to consumers.

Name

M42

Legal name

M42 Ltd

Website

https://m42.ae

Company type

Private

Founded year

2023

Operating status

Operating

Headcount range

5,001–10,000 employees

Ownership category

akta.pro rank

Product category

Integrated Healthcare Services

NAICS

Health Care and Social Assistance (62), General Medical and Surgical Hospitals (62211), Specialty (except Psychiatric and Substance Abuse) Hospitals (622310), Medical and Diagnostic Laboratories (62151), General Medical and Surgical Hospitals (622110)

SIC

Services-Health Services (8000), Services-Hospitals (8060), Services-General Medical & Surgical Hospitals, Nec (8062), Services-Skilled Nursing Care Facilities (8051), Services-Medical Laboratories (8071)

akta.pro primary industry

EHR/EMR Integration & Interoperability Middleware (HL7/FHIR) (HLALAKAD)

akta.pro secondary industries

Virtual Nursing, Telemonitoring & Command Center Platforms (HLACAFAH), Medical Device Connectivity & Interoperability Middleware (MDI, EHR/HL7/FHIR Integration) (HLACAPAJ), Clinical Trial Informatics (EDC/CTMS/eCOA/eTMF) (HLAGAJAM), Healthcare On‑Demand Platforms (Telehealth, Home Care, Nursing) (BPAMAHAH), Chronic Condition Management & Remote Monitoring (e.g., diabetes, HTN) (HLALADAD)

Keywords

• Integrated healthcare services
• Clinical genomics services
• Health information exchange
• Precision medicine platform
• AI-enabled diagnostics

Headquarters

HQ city

Abu Dhabi

HQ country

United Arab Emirates

HQ region

Middle East

Offices7 records

Markets served

GTM type

B2B and B2C

Offering type

Services

Cost components

Personnel, Infrastructure, Operations, Technology or R&D, Marketing or Sales, Supply Chain

Revenue model

1. Healthcare Services Delivery: M42 generates revenue through providing comprehensive healthcare services across its network of 480 clinics in 27 countries, serving 15 million patients annually. Services include tertiary care (Cleveland Clinic Abu Dhabi), dialysis (Diaverum), specialty hospitals, diagnostic services, and primary care, with revenue derived from patient payments, insurance reimbursements, and government healthcare contracts
2. Genomics & AI Platform Services: M42 offers its genomic sequencing capabilities and AI-powered patient management platforms to governments and pharmaceutical companies globally, positioning itself as a B2B service provider for precision medicine infrastructure
3. Medical Tourism: Cleveland Clinic Abu Dhabi reported 35% growth in international patient volume for 2024, with over 10,000 international patient encounters, primarily from Kuwait, Saudi Arabia, Pakistan, Bahrain, and USA, representing a growing revenue stream

Pricing tiers

Go-to-market motion3 records

Distribution channels6 records

Marketing channels7 records

Core offering

M42 is a global tech-enabled health company that delivers integrated clinical care, AI-powered digital health platforms, precision medicine programs, and life sciences services through four platforms: Global Patient Care (480 clinics across 27 countries serving 15 million patients annually), Digital Health Solutions (Malaffi HIE, OSSI ambient AI, Sahatna app), Integrated Health Solutions (Emirati Genome Programme, Abu Dhabi Biobank, Biogenix Labs, IROS), and AI Life Sciences. Its offerings span tertiary hospital care, dialysis services, specialty clinics, genomics, population health programs, and clinical AI platforms such as Med42 and kidney.com.

Product overview

M42 is a global tech-enabled health company operating a platform-plus-modules architecture across four integrated platforms: Global Patient Care (healthcare delivery with 480 clinics across 27 countries), Digital Health Solutions (AI-driven innovations including Malaffi HIE, OSSI ambient AI, and Sahatna app), Integrated Health Solutions (population health including Emirati Genome Program, Abu Dhabi Biobank, Biogenix Labs, and IROS CRO), and AI Life Sciences (drug discovery and development). The company offers specialized clinical services through acquired brands including Cleveland Clinic Abu Dhabi, Danat Al Emarat, Diaverum, Moorfields Eye Hospital, Healthpoint, Imperial College London Diabetes Centre, National Reference Laboratory, Amana Healthcare, and others. Key AI-powered products include Med42 (70B parameter Clinical LLM), kidney.com (AI kidney health education), OSSI (ambient AI clinical assistant), and Malaffi (health information exchange).

Differentiator

Problem solved

Functional benefit

Brands

• Malaffi: Region's premier Health Information Exchange (HIE) platform connecting public and private healthcare providers in Abu Dhabi
• Abu Dhabi Health Data Services (ADHDS)
• Emirati Genome Program
• Abu Dhabi Biobank
• Biogenix Labs
• IROS
• Environmental Sciences
• Diaverum
• kidney.com
• OSSI
• Sahatna
• Gensense

Products and services

• Global Patient Care Integrated healthcare delivery platform operating 480 clinics across 27 countries, serving 15 million patients annually with services from primary care to complex tertiary treatments, delivered through specialized hospital brands.
• Digital Health Solutions AI-driven digital health platform scaling innovations to improve patient outcomes, encompassing Malaffi HIE, OSSI ambient AI clinical assistant, and Sahatna mobile app.
• Integrated Health Solutions Population health platform driving national programs through precision, prevention, and predictive care, including the Emirati Genome Programme, Abu Dhabi Biobank, Biogenix Labs, IROS CRO, and Environmental Sciences.
• Cleveland Clinic Abu Dhabi 394-bed (expandable to 490) tertiary care hospital with 15 institutes providing complex and critical care, ranked UAE and GCC's number one hospital in Newsweek's 2023 'World's Best Hospitals' list.
• Diaverum World's third-largest dialysis provider operating 450 facilities across 24 countries, treating 42,000 patients annually with 13,500 healthcare professionals, providing hemodialysis, peritoneal dialysis, home care, and holiday dialysis services.
• Danat Al Emarat

Quantifiable outcome

• 35% increase in international patient volume at Cleveland Clinic Abu Dhabi in 2024
• +5 more outcomes

Named customers10 records

Segments5 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration5 records

AI capability12 records

Feature9 records

Partnerships

21 partnerships are on record, tiered core, minor and major.

• Mammoth BiosciencescoreStrategic or Co-development Partner · 25 June 2026Abu Dhabi's Department of Health, M42, and US-based Mammoth Biosciences signed MoU at BIO International Convention 2026 to develop CRISPR gene-editing therapies for rare and inherited diseases. Partnership leverages insights from Emirati Genome Programme, includes plans to introduce Mammoth's MB-111 clinical candidate, establish advanced therapy manufacturing capabilities starting with LNP production, and develop local expertise in gene-editing.
• Masdar CitycoreStrategic or Co-development Partner · 25 June 2026Masdar City partnered with M42 and Attentive Science to launch Biosphere Labs, the GCC's first commercially scaled shared laboratory facility for biotechnology, announced at BIO International Convention 2026. The facility provides researchers, startups, and biotech companies with specialized bench space, advanced equipment, and connections to Abu Dhabi's life sciences ecosystem through the HELM cluster.
• Attentive SciencecoreStrategic or Co-development Partner · 25 June 2026Attentive Science partnered with M42 and Masdar City to develop Biosphere Labs, the GCC's first commercially scaled shared laboratory facility for biotechnology. The facility provides specialized laboratory space, advanced equipment, operational support, and industry networks to reduce barriers to scientific research.
• RCSI Medical University of BahrainminorImplementation/ SI/ Consulting Partner · 17 June 2026Amana Healthcare Bahrain signed MoU with RCSI Medical University of Bahrain to expand clinical training and research pathways for students through access to real-world care environments. Collaboration supports joint research initiatives aligned with national healthcare priorities and workforce development.
• QritivecoreTechnology or Integration · 9 June 2026M42's National Reference Laboratory partnered with digital pathology innovator Qritive to introduce AI-powered prostate cancer diagnostics in the UAE. The platform analyzes digital pathology slides to help detect prostate cancer, assess tumor patterns, and support grading according to ISUP criteria, integrated at Cleveland Clinic Abu Dhabi.
• BayanatminorStrategic or Co-development Partner · 8 June 2026UAE-based companies Bayanat and M42 led a pioneering scientific study analyzing ocean water and sailor health data from the 2022 Golden Globe Race, collecting samples from remote parts of four oceans to study microplastics and effects of long-distance voyage on health. Water samples tested at Central Testing Labs using G42 Healthcare's AI-based analytical platforms.
• Arcera Life SciencescoreStrategic or Co-development Partner · 3 June 2026M42 and Arcera Life Sciences signed MoU to advance biopharma localization and healthcare innovation in Abu Dhabi. The partnership focuses on genomics-informed therapeutic development, clinical development acceleration, advanced biobanking and stem cell therapies, and digital AI-enabled transformation across the life sciences value chain.
• Abu Dhabi Quality and Conformity CouncilcoreStrategic or Co-development Partner · 11 May 2026Abu Dhabi Quality and Conformity Council activated advanced blood toxicology testing services through the Central Testing Laboratory in collaboration with M42. The service enables detection of heavy metals and toxic agents in blood within hours instead of days or weeks, eliminating reliance on overseas laboratories.
• Global Medical Supply Chain (GMSC)coreImplementation/ SI/ Consulting Partner · 8 May 2026M42 and Global Medical Supply Chain (GMSC), a subsidiary of Mubadala Bio, signed outsourcing agreement for GMSC to manage integrated medical supply chain services across M42's healthcare network in UAE. Partnership covers sourcing, procurement, warehousing, inventory management, and distribution of pharmaceuticals, medical equipment, and healthcare consumables.
• TELUS HealthmajorGTM or Marketing Partner · 11 February 2026M42's Digital Health Solutions partnered with TELUS Health to introduce AI-powered employee wellbeing services in the UAE at Dubai World Health Expo 2026. Collaboration deploys an Employee Assistance Program with over 40 modules covering emotional health, lifestyle management, and wellbeing, delivered in local languages to improve workplace productivity.
• 10X HealthmajorStrategic or Co-development Partner · 7 November 202510X Health and REVIV Global partnered with M42 to launch 10XREVIV, a wellness brand in Abu Dhabi combining diagnostics, personalized health plans, and nutrient therapies. The initiative aims to position Abu Dhabi as a hub for wellness and longevity healthcare with plans for regional expansion, establishing clinics and conducting clinical trials.
• REVIV GlobalmajorStrategic or Co-development Partner · 7 November 2025REVIV Global partnered with M42 and 10X Health to launch 10XREVIV in Abu Dhabi, integrating genetic science, AI, and biomarker analysis for personalized health optimization. The partnership will establish a flagship clinic, undertake clinical trials, and develop educational programs focused on longevity and precision nutrition.
• Oracle HealthcoreTechnology or Integration · 3 November 2025M42 and Oracle Health signed strategic collaboration to integrate data from Emirati Genome Program into electronic health records, enabling pharmacogenomic recommendations at point of care across the UAE. Partnership uses Oracle Health Foundation EHR to create unified longitudinal patient records and shift healthcare from reactive to proactive, preventive care.
• Olive Rock PartnerscoreStrategic or Co-development Partner · 27 October 2025M42 and Olive Rock Partners agreed strategic alignment of assets: M42 acquired 100% ownership of United Eastern Medical Services (including Danat Al Emarat, Moorfields Abu Dhabi, HealthPlus Family Health), while Olive Rock Partners took 100% ownership of HealthPlus IVF and Women's Health Abu Dhabi. Transaction completed in 2025.
• Medical Tourism AssociationmajorGTM or Marketing Partner · 10 October 2025M42 partnered with Medical Tourism Association (MTA) and Mastercard to promote UAE as a medical tourism hub. The collaboration features M42's facilities on the Better by MTA platform to streamline cross-border healthcare services and payments.
• CerebrascoreTechnology or Integration · 7 March 2025M42 collaborated with Cerebras to develop Med42, a 70 billion parameter open-access Clinical LLM. Full-parameter fine-tuning was accomplished on Cerebras and G42's Condor Galaxy 1 (CG-1) AI supercomputer. Med42 achieves 72% on USMLE Sample Exam questions and is available on Hugging Face for non-commercial use.
• Mohamed bin Zayed University of Artificial IntelligencecoreStrategic or Co-development Partner · 7 March 2025MBZUAI collaborated with M42 and Core42 to evaluate Med42 clinical LLM, contributing to the development and validation of the 70 billion parameter open-access clinical model designed to enhance clinical decision-making.
• GE HealthCaremajorTechnology or Integration · 1 January 2025M42 collaborated with GE HealthCare to advance AI-enabled diagnostics, genomics, and cancer treatment infrastructure as part of its comprehensive strategy to position itself as a global leader in precision, preventive, and personalised healthcare.
• AstraZenecamajorStrategic or Co-development Partner · 1 January 2025M42 partnered with AstraZeneca to advance AI-enabled diagnostics and cancer treatment infrastructure, supporting the company's strategy for precision medicine and healthcare innovation.
• Mumtalakat Holding CompanycoreStrategic or Co-development Partner · 24 September 2024Mumtalakat Holding Company partnered with Amana Healthcare (part of M42) to develop a specialized healthcare facility in Al Jasra, Bahrain. The 15,000 sqm, 100-bed facility is Bahrain's first international premium provider of specialized long-term care and post-acute rehabilitation services, scheduled to commence operations in 2025.
• DiaverumcoreStrategic or Co-development Partner · 19 April 2023M42 acquired 100% of Diaverum shares from Bridgepoint Group for approximately $2.5 billion in 2023. Diaverum is the world's third-largest dialysis provider operating 450 facilities across 24 countries, treating 42,000 patients annually with 13,500 healthcare professionals. The acquisition expanded M42's geographic footprint and enhanced its kidney care offerings with tech-enabled care solutions.

Scale indicators20 records

Recent moves9 records

Expansion highlights6 records

Direct peers

• Fresenius Medical Care: World's largest dialysis provider and integrated renal care company; directly comparable to M42's Diaverum subsidiary as both operate vertically integrated dialysis platforms across multiple geographies with recurring chronic-care revenue.
• DaVita: World's second-largest dialysis provider operating 3,000+ outpatient clinics across 12+ countries; directly comparable to M42's Diaverum business in scale, chronic renal care model, and technology-enabled care delivery.
• Aster DM Healthcare: Middle East and India-headquartered hospital and clinic operator with 1,400+ facilities across 7 countries; directly comparable to M42 as a regional hospital group with cross-border expansion, multi-specialty focus, and GCC market presence.
• IHH Healthcare: Asia-Pacific hospital operator (Mount Elizabeth, Gleneagles, Acibadem) with premium tertiary care, multi-country footprint, and medical tourism positioning—comparable as a multi-geography premium hospital group pursuing technology-enabled care delivery.

Emerging players

• Teladoc Health: Global virtual care and telehealth platform offering chronic-condition management, behavioral health, and AI-enabled patient engagement; partially comparable to M42's Sahatna app, kidney.com, and Digital Health Solutions portfolio targeting consumer virtual care and chronic-disease management.

Regional players

• Mediclinic International: International private hospital group operating across Southern Africa, the Middle East (UAE), and Switzerland; comparable as a multi-geography premium hospital operator with significant UAE presence competing for medical tourism and high-acuity cases.

Broad incumbents

• Oracle Health (Cerner): Enterprise EHR and health data platform; directly comparable to M42's Malaffi HIE and OSSI platforms, and now a strategic partner integrating Emirati Genome data into Oracle Health Foundation EHRs.
• GE HealthCare: Global medical technology and diagnostics company with AI-enabled imaging, genomics, and care delivery solutions; comparable to M42's Digital Health Solutions and Integrated Health Solutions platforms, and a current M42 partner for AI-enabled diagnostics and cancer treatment.
• HCA Healthcare: Largest US for-profit hospital operator with 190+ hospitals and significant investment in clinical AI and digital health infrastructure—comparable as a large-scale integrated hospital operator pursuing technology-enabled care at scale.
• Cleveland Clinic: Operates Cleveland Clinic Abu Dhabi in partnership with M42; a US-based multi-specialty academic medical center globally recognized for tertiary care, medical research, and brand-driven medical tourism—comparable as the brand operator behind M42's flagship tertiary hospital.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat7 records

Key risks6 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/@M42_ae
• Facebookfacebook.com/M42UAE
• LinkedInlinkedin.com/company/m42uae
• Instagraminstagram.com/m42_ae

Compliance12 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles14 records

Subsidiaries19 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A2 records

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about M42